198 related articles for article (PubMed ID: 20393638)
61. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
Boland CL; Degeeter M; Nuzum DS; Tzefos M
Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
[TBL] [Abstract][Full Text] [Related]
62. FDA approves saxagliptin for type 2 diabetes.
Traynor K
Am J Health Syst Pharm; 2009 Sep; 66(17):1513. PubMed ID: 19710429
[No Abstract] [Full Text] [Related]
63. Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial.
Leiter LA; Teoh H; Mosenzon O; Cahn A; Hirshberg B; Stahre CA; Hoekstra JB; Alvarsson M; Im K; Scirica BM; Bhatt DL; Raz I;
Diabetes Obes Metab; 2016 Feb; 18(2):186-90. PubMed ID: 26443993
[TBL] [Abstract][Full Text] [Related]
64. Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden.
Granström O; Bergenheim K; McEwan P; Sennfält K; Henriksson M
Prim Care Diabetes; 2012 Jul; 6(2):127-36. PubMed ID: 22001114
[TBL] [Abstract][Full Text] [Related]
65. Efficacy of saxagliptin as an add-on to oral monotherapy in the phase 3 clinical development program: predictive factors of the treatment response in type 2 diabetes.
Gautier JF; Sauvanet JP
Ann Endocrinol (Paris); 2011 Sep; 72(4):287-295. PubMed ID: 21777901
[TBL] [Abstract][Full Text] [Related]
66. SGLT2 inhibitor/DPP-4 inhibitor combination therapy - complementary mechanisms of action for management of type 2 diabetes mellitus.
Dey J
Postgrad Med; 2017 May; 129(4):409-420. PubMed ID: 28322073
[TBL] [Abstract][Full Text] [Related]
67. The dipeptidyl peptidase-4 inhibitor saxagliptin improves function of circulating pro-angiogenic cells from type 2 diabetic patients.
Poncina N; Albiero M; Menegazzo L; Cappellari R; Avogaro A; Fadini GP
Cardiovasc Diabetol; 2014 May; 13():92. PubMed ID: 24886621
[TBL] [Abstract][Full Text] [Related]
68. Saxagliptin and risk of heart failure hospitalization: Concern or miscalculation?
Cebrián-Cuenca AM; Orozco-Beltrán D; Navarro-Pérez J; Franch-Nadal J; Núñez-Villota J; Consuegra-Sánchez L
Int J Cardiol; 2016 Oct; 220():573-4. PubMed ID: 27390991
[No Abstract] [Full Text] [Related]
69. Saxagliptin alters bile acid profiles and yields metabolic benefits in drug-naïve overweight or obese type 2 diabetes patient.
Li W; Liu R; Li X; Tao B; Zhai N; Wang X; Li Q; Zhang Y; Gu W; Wang W; Ning G
J Diabetes; 2019 Dec; 11(12):982-992. PubMed ID: 31141297
[TBL] [Abstract][Full Text] [Related]
70. Saxagliptin, alogliptin, and cardiovascular outcomes.
Scirica BM; Braunwald E; Bhatt DL
N Engl J Med; 2014 Jan; 370(5):483-4. PubMed ID: 24476444
[No Abstract] [Full Text] [Related]
71. Saxagliptin co-therapy in C-peptide negative Type 1 diabetes does not improve counter-regulatory responses to hypoglycaemia.
George PS; McCrimmon RJ
Diabet Med; 2016 Sep; 33(9):1283-90. PubMed ID: 26642301
[TBL] [Abstract][Full Text] [Related]
72. Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials.
Iqbal N; Parker A; Frederich R; Donovan M; Hirshberg B
Cardiovasc Diabetol; 2014 Feb; 13():33. PubMed ID: 24490835
[TBL] [Abstract][Full Text] [Related]
73. Acute and long-term effects of saxagliptin on post-prandial glycemic response in obese patients with impaired glucose tolerance.
Rezki A; Fysekidis M; Chiheb S; Vicaut E; Cosson E; Valensi P
Nutr Metab Cardiovasc Dis; 2021 Apr; 31(4):1257-1266. PubMed ID: 33618922
[TBL] [Abstract][Full Text] [Related]
74. ACP Journal Club. In at-risk patients with type 2 diabetes, saxagliptin and placebo did not differ for CV events.
Morey-Vargas OL; Montori VM
Ann Intern Med; 2014 Jan; 160(2):JC8-9. PubMed ID: 24445719
[No Abstract] [Full Text] [Related]
75. Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin.
Pollack PS; Chadwick KD; Smith DM; Billger M; Hirshberg B; Iqbal N; Boulton DW
Cardiovasc Diabetol; 2017 Sep; 16(1):113. PubMed ID: 28903775
[TBL] [Abstract][Full Text] [Related]
76. Prospective Postmarketing Surveillance of Acute Myocardial Infarction in New Users of Saxagliptin: A Population-Based Study.
Toh S; Reichman ME; Graham DJ; Hampp C; Zhang R; Butler MG; Iyer A; Rucker M; Pimentel M; Hamilton J; Lendle S; Fireman BH;
Diabetes Care; 2018 Jan; 41(1):39-48. PubMed ID: 29122893
[TBL] [Abstract][Full Text] [Related]
77. Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes.
Ott C; Raff U; Schmidt S; Kistner I; Friedrich S; Bramlage P; Harazny JM; Schmieder RE
Cardiovasc Diabetol; 2014 Jan; 13():19. PubMed ID: 24423149
[TBL] [Abstract][Full Text] [Related]
78. Effects of saxagliptin on glucose homeostasis and body composition of obese patients with newly diagnosed pre-diabetes.
Wang Z; Xu D; Huang L; Zhang T; Wang J; Chen Q; Kong L; Zhou X
Diabetes Res Clin Pract; 2017 Aug; 130():77-85. PubMed ID: 28575729
[TBL] [Abstract][Full Text] [Related]
79. Dipeptidyl peptidase-4 inhibitors and cardiovascular safety.
Davis TM
Med J Aust; 2014 May; 200(8):450-1. PubMed ID: 24794596
[No Abstract] [Full Text] [Related]
80. Dipeptidyl Peptidase-4 Inhibitors and Heart Failure Exacerbation in the Veteran Population: An Observational Study.
Cobretti MR; Bowman B; Grabarczyk T; Potter E
Pharmacotherapy; 2018 Mar; 38(3):334-340. PubMed ID: 29364549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
